Scientific Session I: Neuropathology

We will start with a neuropathology table proposing that co-pathology is the norm in dementia, and most patients have several components: tau, amyloid, tdp43, alpha-synuclein.

CHAIRPERSON: Alberto Rábano . BTCIEN-Fundación CIEN.

Gabor Kovacs . Laboratory Medicine & Pathobiology. University of Toronto. (On-line)

“Title”

TBD

“Title”

Scientific Session II: Genetic variability

In the following table, we will address how genetic variability is associated with the risk of AD and with most of the frequent AD co-pathologies (alpha-synuclein, TDP43, vascular…) and can potentially be applied to diagnostic and/or risk classification. We will also explore brain resilience from a genetic perspective.

CHAIRPERSON: Agustín Ruiz

Alfredo Ramírez , Cluster of Excellence for Aging Research. University of Cologne.

“Title”

Henne Holstege , Alzheimer Center Amsterdam. VUmc. Amsterdam UMC

“Title”

SCIENTIFIC SESSION III: Neuroimaging

We will deepen into neuroimaging techniques for detecting different dementia-related patterns reflecting the disease components.

CHAIRPERSON: Michel Grothe

David Wolk , Laboratory for Cognition and Neural Stimulation. University of Pennsylvania

"Title"

Jesús Silva. , Fundación CIEN
"Title"

Laura Jonkman, Amsterdam Neuroscience - Brain Imaging (VUmc). Amsterdam UMC

"Title"

SCIENTIFIC SESSION IV: Biomarkers

Discussing the detection of neuropathological components in the periphery using biochemical markers.

CHAIRPERSON: Pascual Sánchez Juan Fundación CIEN

Gemma Salvadó , Clinical Memory Research. Lund University

"Title"

Anja Schneider, Translational Dementia Research. German Center for Neurodegenerative Diseases-DZNE. University of Bonn.

"Title"

Scientific Session V: Pharmacological intervention

We will discuss pharmacological intervention, specifically tackling some of the main pathological components of dementia.

CHAIRPERSON: Alberto Lleó, Unidad de Memoria. Hospital de Sant Pau

TBD, Amyloid
"Title"

TBD, Tau
"Title"

TBD, Inflammation
"Title"

Scientific Session VI: Non-pharmacological interventions

Non-pharmacological interventions. Here, we will discuss non-pharmacological interventions and the available evidence addressing the pathological components.

CHAIRPERSON: Joe Paton, Paton Lab. Champalimaud Foundation - Jhon Krakauer. Krakauer Lab. Champalimaud Foundation - Joaquim Ferreira. CNS. University of Lisbon.

Preventive Multidomain personalized interventions

Miia Kivipelto, Center for Alzheimer Research. Karolinska Institutet.Stockholm
"Title"

Pablo Martínez Lage., Fundación CITA Alzheimer. Donostia
"Title"

Behavioral interventions

The role of exercise in dementia prevention

Quantifying non-pharmacological intervention's effect through Digital markets

Posters

Scientific Session VII

Round table with patients/relatives from Spain and Portugal

Doctor-patient communication in CD, (Neurologists: Alberto Lleó, Unidad de Memoria. Hospital de Sant Pau - -Pascual Sánchez-Juan, Fundación CIEN; Clinicians from Portugal: Joaquim Ferreira, CNS. University of Lisbon.
Disclosing information in unimpaired individuals at risk Biomarkers, (Neurologists: Alberto Lleó, Unidad de Memoria. Hospital de Sant Pau - Pascual Sánchez-Juan, Fundación CIEN - -Clinicians from Portugal: Joaquim Ferreira (CNS. University of Lisbon).

Geneticists: Agustín Ruiz, Fundaciò ACE.

Spanish Patients Association CEAFA, Mariló Almagro, Confederación Española de Alzheimer y otras demencias (CEAFA).
Spanish Patients panel PEPA, Kina García, Panel de expertos de personas con Alzheimer (PEPA).

Portuguese Patients Associations

OFFICIAL CLOSING BY HER MAJESTY QUEEN SOFÍA OF SPAIN